Time for active surveillance of intermediate-risk disease?

Nature Reviews Urology

Volumn 10, Issue 1, 2013, Pages 6-8

  Ahmed, Hashim U ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANXIETY; ARTICLE; CANCER CLASSIFICATION; CANCER CONTROL; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; EMOTION; FOLLOW UP; HEALTH PROGRAM; HUMAN; IMPOTENCE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PATIENT CARE; PATIENT SAFETY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM BIOPSY; RECTUM DISEASE; URINE INCONTINENCE; AGED; BLOOD; CANCER STAGING; COMPUTER ASSISTED RADIOTHERAPY; DECISION MAKING; EVIDENCE BASED MEDICINE; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TIME; TUMOR INVASION; UNITED KINGDOM; WATCHFUL WAITING;

AGED; DECISION MAKING; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS; WATCHFUL WAITING;

EID: 84871922236     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.213     Document Type: Article

References (10)

1. Bul, M. et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. http://dx.doi.org/10.1111/j.1464-410X.2012.11434.x.
2. Godtman, R. A., Holmberg, E., Khatami, A., Stranne, J. & Hugosson, J. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg Randomised Population-based Prostate Cancer Screening Trial. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2012.08. 066.
3. Dahabreh, I. J. et al. Active surveillance in men with localized prostate cancer: a systematic review. Ann. Intern. Med. 156, 582-590 (2012).
4. McVey, G. P. et al. Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int. 106, 1161-1164 (2010).
5. Cooperberg, M. R., Lubeck, D. P., Meng, M. V., Mehta, S. S. & Carroll, P. R. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J. Clin. Oncol. 22, 2141-2149 (2004).
6. King, M. T. et al. Survival gains needed to offset persistent adverse treatment effects in localised prostate cancer. Br. J. Cancer 106, 638-645 (2012).
7. Wilt, T. J. et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367, 203-213 (2012).
8. Klotz, L. et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28, 126-131 (2010).
9. Ahmed, H. U. et al. Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol. 13, 622-632 (2012).
10. Ahmed, H. U., Arya, M., Freeman, A. & Emberton, M. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? Lancet Oncol. 13, e509-e517 (2012).